Dear Sir, We would like to take part in the debate about the discontinuation of treatment of
chronic myeloid leukaemia (CML), with particular reference to the Letter to the Editor by …

Conversely, about 40% of patients maintain a complete molecular response after withdrawal
of tyrosine kinase inhibitor treatment. It is interesting to note that previous treatment with …

Philadelphia (Ph)-chromosome-positive chronic myeloid leukemia (CML) with the e19a2
rearrangement encoding p230 protein is a rare disease with varying clinical presentation …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder, characterized by the
presence of the Philadelphia (Ph) chromosome, a consequence of a reciprocal translocation …

Dear Sir, We read with interest the article by Srinivas et al.[1] describing morphological
changes in bone marrows of chronic myeloid leukemia (CML) patients treated with imatinib …

Descriptions of chromosomally abnormal Philadelphia-negative (PhJ) clones in chronic
myeloid leukemia (CML) patients treated with chemotherapy, 1 interferon-alpha, 2 and, most …

Short-term results with imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Hanover, NJ)
for chronic-phase chronic myelogenous leukemia (CML) are extremely encouraging, with …

Since the introduction of imatinib as the first-line therapy in chronic phase chronic myeloid
leukemia (CML), the prognosis for patients has dramatically improved. 1 As female patients …

We read with interest the letter by Chee et al1 reporting a case of chronic myeloid leukemia
(CML) with a fatal myelodysplastic syndrome developing during imatinib mesylate therapy …

Dear Editor, The Philadelphia chromosome (Ph), produced by the reciprocal t (9; 22)(q34;
q11. 2), is the cytogenetic hallmark of chronic myeloid leukemia (CML) and is observed in …